Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
AuthorsBoard, Ruth E
Orr, M C M
Kemsley, K R
Blockley, L Y
Dearden, S P
Ranson, Malcolm R
Cantarini, M V
AffiliationAstraZeneca Pharmaceuticals, Alderley Park, Cheshire SK10 4TG, UK.
MetadataShow full item record
AbstractBACKGROUND: This study investigated the potential clinical utility of circulating free DNA (cfDNA) as a source of BRAF mutation detection in patients enrolled into a phase II study of AZD6244, a specific MEK1/2 inhibitor, in patients with advanced melanoma. METHODS: BRAF mutations were detected using Amplification Refractory Mutation System allele-specific PCR. BRAF mutation status was assessed in serum-derived cfDNA from 126 patients enrolled into the study and from 94 matched tumour samples. RESULTS: Of 94 tumour samples, 45 (47.9%) were found to be BRAF mutation positive (BRAF+). Serum-derived cfDNA was BRAF+ in 33 of 126 (26.2%) samples, including in five samples for which tumour data were unavailable. Of BRAF+ tumours, 25 of 45 (55.6%) were BRAF+ in cfDNA. In three cases in which the tumour was negative, cfDNA was BRAF+. Progression-free survival (PFS) of patients with BRAF+ tumour and cfDNA was not significantly different compared with tumour BRAF+ but cfDNA BRAF-negative patients, indicating that cfDNA BRAF detection is not associated with poorer prognosis on PFS in stage III/IV advanced melanoma. CONCLUSIONS: These data demonstrate the feasibility of BRAF mutation detection in cfDNA of patients with advanced melanoma. Future studies should aim to incorporate BRAF mutation testing in cfDNA to further validate this biomarker for patient selection.
CitationDetection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. 2009, 101 (10):1724-30 Br. J. Cancer
JournalBritish Journal of Cancer
- Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.
- Authors: Aung KL, Donald E, Ellison G, Bujac S, Fletcher L, Cantarini M, Brady G, Orr M, Clack G, Ranson M, Dive C, Hughes A
- Issue date: 2014 May
- BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
- Authors: Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R
- Issue date: 2015 Dec
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
- Authors: Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM
- Issue date: 2016 Feb 1
- Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
- Authors: Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB
- Issue date: 2013 Feb 15
- A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
- Authors: Boers-Sonderen MJ, Desar IM, Blokx W, Timmer-Bonte JN, van Herpen CM
- Issue date: 2012 Aug